The biopharmaceutical company, Gilead Sciences, has taken the decision to close its research and development operations in Durham, North Carolina. The closure will lead to biotechnology job cuts.
The company plans to close its Durham operations by the end of the year. They plan to consolidate its research and development work on treatments for hepatitis B and C to its headquarters in Foster City, California.
The biopharmaceutical company employs around 4,000 people around the world and it’s annual revenues surpassed $7 billion. Their primary areas of research include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
Looking for a new position in the biotechnology industry? Click here to search our current biotechnology jobs now.